{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:09:16Z","timestamp":1788822556895,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Menarini International Operations Luxembourg"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Hyperuricaemia and gout are strongly related with traditional cardiovascular risk factors and vascular damage. This study aimed to assess whether febuxostat and allopurinol could differently influence carotid-femoral pulse wave velocity (cfPWV) in patients with gout and elevated serum uric acid (SUA) levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>A multi-centre, multinational, phase IV, randomized, parallel-group, active-controlled, open-label trial with blind endpoints evaluation. One hundred and ninety-seven adults with gout and SUA levels \u22658\u2009mg\/dL were randomized to febuxostat or allopurinol in a 1:1 ratio for 36\u2009weeks. The primary outcome was the comparison of the effects of febuxostat and allopurinol on changes in cfPWV. The mean cfPWV values at randomization and Week 36 were 8.69 and 9.00\u2009m\/s, respectively for subjects randomized to febuxostat and 9.02 and 9.05\u2009m\/s for subjects randomized to allopurinol. No statistically significant changes in cfPWV by treatment assignment were observed at any time point for any of the assessed parameters. More subjects who received febuxostat had serum urate concentrations \u22646\u2009mg\/dL following treatment (78.3% vs. 61.1% at Week 36, P\u2009=\u20090.0137). Treatment-emergent adverse events were reported by 51 (52.0%) patients randomized to febuxostat and 63 (62.5%) patients randomized to allopurinol. The majority of events were mild in both treatment groups and included gout flares and arthralgia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with gout and elevated SUA levels the arterial stiffness remained stable both with febuxostat and allopurinol. Febuxostat was more effective and faster than allopurinol in achieving the SUA target. Both treatments were safe and well tolerated.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa144","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T20:09:44Z","timestamp":1608408584000},"page":"236-242","source":"Crossref","is-referenced-by-count":21,"title":["Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study"],"prefix":"10.1093","volume":"8","author":[{"given":"Giovambattista","family":"Desideri","sequence":"first","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of l\u2019Aquila , L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Rajzer","sequence":"additional","affiliation":[{"name":"I-st Department of Cardiology Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College , Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Gerritsen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology , Reade, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology & immunology Center | Reade , Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giannattasio","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, Milano Bicocca University and Cardio Center de Gasperis ASST Niguarda , Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Kathrin","family":"Tausche","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Clinic Carl Gustav Carus at the TU Dresden , Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Ospedale Malpighi, University of Bologna , Via Albertoni 15, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.33369","article-title":"Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal","volume":"64","author":"Neogi","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.amjmed.2005.03.043","article-title":"Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?","volume":"118","author":"Baker","year":"2005","journal-title":"Am J Med"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","article-title":"Serum uric acid and the risk of cardiovascular and renal disease","volume":"33","author":"Borghi","year":"2015","journal-title":"J Hypertens"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/HYPERTENSIONAHA.115.06531","article-title":"Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition","volume":"67","author":"Borghi","year":"2016","journal-title":"Hypertension"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.114.03953","article-title":"Allopurinol initiation and change in blood pressure in older adults with hypertension","volume":"64","author":"Beattie","year":"2014","journal-title":"Hypertension"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/annrheumdis-2014-205269","article-title":"Allopurinol initiation and all-cause mortality in the general population","volume":"74","author":"Dubreuil","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00296-013-2857-2","article-title":"As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout","volume":"34","author":"Tausche","year":"2014","journal-title":"Rheumatol Int"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8095825","article-title":"Febuxostat modulates MAPK\/NF-\u03baBp65\/TNF-\u03b1 signaling in cardiac ischemia-reperfusion injury","volume":"2017","author":"Khan","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ajh\/hpy157","article-title":"Xanthine oxidase inhibition by febuxostat in macrophages suppresses angiotensin ii-induced aortic fibrosis","volume":"32","author":"Kondo","year":"2019","journal-title":"Am J Hypertens"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","article-title":"Expert consensus document on arterial stiffness: methodological issues and clinical applications","volume":"27","author":"Laurent","year":"2006","journal-title":"Eur Heart J"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/eurheartj\/ehq024","article-title":"Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis","volume":"31","author":"Vlachopoulos","year":"2010","journal-title":"Eur Heart J"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ajh.2010.111","article-title":"Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension","volume":"24","author":"Vlachopoulos","year":"2011","journal-title":"Am J Hypertens"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00380-008-1127-9","article-title":"Uric acid is an independent predictor of arterial stiffness in hypertensive patients","volume":"24","author":"Tsai","year":"2009","journal-title":"Heart Vessels"},{"key":"2023032402564782800_","first-page":"142","article-title":"The impacts of serum uric acid on arterial hemodynamics and cardiovascular risks","volume":"29","author":"Hsu","year":"2013","journal-title":"Acta Cardiol Sin"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"e91961","DOI":"10.1371\/journal.pone.0091961","article-title":"Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study","volume":"9","author":"Ng","year":"2014","journal-title":"PLoS One"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"117954681877958","DOI":"10.1177\/1179546818779584","article-title":"Effect of xanthine oxidase inhibition on arterial stiffness in patients with chronic heart failure","volume":"12","author":"Alem","year":"2018","journal-title":"Clin Med Insights Cardiol"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.12659\/MSM.898370","article-title":"Effects of allopurinol on arterial stiffness: a meta-analysis of randomized controlled trials","volume":"22","author":"Deng","year":"2016","journal-title":"Med Sci Monit"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","article-title":"Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial)","volume":"77","author":"Sezai","year":"2013","journal-title":"Circ J"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehq165","article-title":"Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: \u2018establishing normal and reference values\u2019","volume":"31","author":"Reference Values for Arterial Stiffness' Collaboration","year":"2010","journal-title":"Eur Heart J"},{"key":"2023032402564782800_","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijcard.2020.01.046","article-title":"Uric acid and estimate of renal function. Let's stick together","volume":"310","author":"Borghi","year":"2020","journal-title":"International Journal of Cardiology"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1440-1681.1999.03125.x","article-title":"Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects","volume":"26","author":"O'Driscoll","year":"1999","journal-title":"Clin Exper Pharmacol Physiol"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/01.HYP.30.1.57","article-title":"Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients","volume":"30","author":"Cardillo","year":"1997","journal-title":"Hypertension"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ajh\/hpy197","article-title":"Xanthine oxidase inhibition as a potential treatment for aortic stiffness in hypertension","volume":"32","author":"Cicalese","year":"2019","journal-title":"Am J Hypertens"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1113\/jphysiol.2005.102566","article-title":"Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing","volume":"571","author":"Eskurza","year":"2006","journal-title":"J Physiol"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2003.11.046","article-title":"Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers","volume":"93","author":"Guthikonda","year":"2004","journal-title":"Am J Cardiol"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000046448.26751.58","article-title":"Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers","volume":"107","author":"Guthikonda","year":"2003","journal-title":"Circulation"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.HYP.35.3.746","article-title":"Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension","volume":"35","author":"Butler","year":"2000","journal-title":"Hypertension"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"e1003095","DOI":"10.1371\/journal.pmed.1003095","article-title":"Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial","volume":"17","author":"Tanaka","year":"2020","journal-title":"PLoS Med"},{"key":"2023032402564782800_","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa144\/35499555\/pvaa144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/3\/236\/49615188\/pvaa144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/3\/236\/49615188\/pvaa144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:50:35Z","timestamp":1724082635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/3\/236\/6067402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa144","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2021,1,15]]}}}